Objective. To estimate the nonadherence rate of pressure equalization (tympanostomy) tube (PET) placement in the preceding 3-year period before release of the 2013 American Academy of Otolaryngology-Head and Neck Surgery Foundation clinical practice guideline (CPG).
O titis media (OM) is the most frequent diagnosis for which children present to the pediatrician and the leading reason for childhood antimicrobial prescriptions. 1 Pressure equalization (tympanostomy) tube (PET) insertion is the most commonly performed ambulatory surgical pediatric procedure in the United States. 2 OM has a high socioeconomic impact, with an estimated cost of $4 billion per year. 3 Published guidelines exist on management of acute OM (AOM) and OM with effusion (OME). 4, 5 However, no guidelines prior to 2013 provided specific indications for PET insertion. Two studies 6, 7 suggested that most PET placements were inappropriate according to criteria derived from expert consensus. These authors concluded that many PET insertions were inappropriate due to short duration of OME (mean \30 days). They determined that nearly 50% of cases were inappropriate or equivocal even when known risk factors were taken into account. In response to this lack of clarity on best practices for surgical management of OME, the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) convened a multidisciplinary group in 2012 to develop an evidencebased clinical practice guideline (CPG) for the specific indication of PET placement in children. 2 The AAO-HNSF CPG contains 12 individual key action statements (KASs) that have relevance to compliance, best practice, and opportunities for quality improvement.
We used the Truven Health MarketScan Research Databases (3 years, 2010-12) to determine the nonadherence of PET placement in children by KAS ( Table 1) . This guideline builds on itself to provide recommendations for health care providers to manage OME based on duration as well as risk factors and sequelae. We hypothesized that a significant percentage of PET insertions considered inappropriate for effusion duration \90 days (KAS 1) would be significantly reduced once the KASs were examined as an integrated and comprehensive management guide. Integration of all the KASs allows behavioral, balance, and speech language delay to be modifiers of the recommendation for PET insertion. We also sought to identify opportunities for quality improvement in the care of patients with OM. Close examination of nonadherence rates can serve as the baseline to examine changes after dissemination and implementation of the new guideline on PETs. 2 
Methods
Data used for the analysis were extracted from the 2010-2012 Truven Health MarketScan Research Databases (2012, Truven Health Analytics Inc) licensed by and accessed via a collaboration between the AAO-HNSF and the National Institute on Deafness and Other Communication Disordersfunded CHEER network. The data contained in our Truven subset included the following: emergency department, inpatient, outpatient/clinic, and prescription drug claims of employees and dependents covered by a selection of large employers, private and public health plans, and government and public organizations. 8 
Case Selection
Our coding strategy was derived from the KASs of the guideline, vetted by the senior author (D.W.) with the investigative team, and reviewed by the PET CPG primary author (R.M.R.). International Classification of Diseases, Ninth Revision ( Figure 1 ) codes were queried for patients 12 years with at least 1 OM claim ( Figure 2 ) from any clinic visit between January 1, 2010, and December 31, 2012. We used a bracketing strategy for code selection ( Table 1) to reduce errors if clinicians used nonspecific coding (eg, coded for OME but not concurrent hearing loss). The Duke University Health System Institutional Review Board granted the study exemption from further review.
Statement Definitions
The following definitions were used for each KAS and were applied to extract data from the 2010-2012 MarketScan databases to assess adherence to the correspondingly numbered KASs (Table 1) .
For KASs 1 to 5, an episode of OME was defined as a series of visits with OM codes where the time between visits was \6 months. Duration of episode was computed as the time between first and last visits, with ''first visit'' being no preceding diagnosis of OM for 6 months and ''last visit'' being no subsequent diagnosis of OM for 6 months. Patients with tympanic membrane perforation or otorrhea at first visit were excluded.
KAS 1: OME of Short Duration. An episode met the criteria for PET placement if its duration was 3 months (chronic OME). If a PET placement code was found within 3 months of first visit, the episode was labeled nonadherent.
KAS 2: Hearing Testing. In patients with an episode of OME 3 months, adherence was defined as a hearing test performed between 3 and 6 months after first visit.
KAS 3: Chronic Bilateral OME with Hearing Difficulty. For patients who had an episode of OME for 3 months with a hearing test and a hearing loss code 3 to 6 months after first visit, adherence was defined as PET placement within 6 months of the earliest date of hearing loss code.
KAS 4: Chronic OME with Symptoms. For patients with an episode of OME 3 months who received PET without documented hearing test or hearing loss codes but with a potentially related complicating symptom (balance [vestibular] problems, poor school performance, behavioral problems, and ear discomfort), adherence was defined as having a code for at least 1 of the symptoms above.
KAS 5: Surveillance of Chronic OME. For patients who had OME for 3 months and did not receive PET, adherence was defined as presence of a code for OM within 6 months prior to the date of a hearing loss or structural abnormality code suggesting appropriate surveillance.
KASs 6 and 7: Recurrent AOM with and without Effusion. An episode of AOM was defined as a series of visits with an AOM-related code where the time between visits was \30 days. Determining the physical presence of middle ear effusion (MEE) was not possible from this data set; therefore, hearing loss was used as a surrogate marker. Candidates for tubes had 3 separate well-documented AOM episodes in 6 months or at least 4 separate welldocumented AOM episodes in 12 months with at least 1 in the past 6 months. Adherence for KAS 6 was defined as no PET insertion within 6 months of the last visit for AOM if no hearing loss code at last visit. Adherence for KAS 7 was defined as PET insertion within 6 months of the last visit for AOM if hearing loss code at the last visit.
KASs 8 and 9: Tubes and At-Risk Children. ''At risk'' indicates patients who are at risk for speech, language, or learning problems from OM owing to baseline sensory, physical, cognitive, or behavioral factors. The guideline specifically mentions permanent hearing loss, speech delay, autism, 5: Surveillance of chronic OME.
Clinicians should reevaluate at 3-to 6-month intervals children with chronic OME who do not receive tympanostomy tubes, until the effusion is no longer present, significant hearing loss is detected, or structural abnormalities of the tympanic membrane or middle ear are suspected.
Population from KAS 1 with OM episode .3 mo were assessed for hearing loss code or structural abnormality code. The presence of a code for OM within 6 mo prior to the hearing loss or structural abnormality code was used as a surrogate for surveillance.
27,929 25,590 (91.6) Table 2 ). syndromes/craniofacial disorders, blindness, cleft palate, and developmental delay. For KAS 8, patients with an episode of OM of any duration were assessed for the above conditions. For KAS 9, patients with an episode of OM for 3 months who received PET without documented hearing difficulties were assessed for the presence of the above conditions. Adherence was defined as having 1 baseline sensory, physical, cognitive, or behavioral factor within 6 months prior to getting PET.
KAS 11: Acute Tympanostomy Tube Otorrhea. Patients who had a code for PET and AOM and/or otorrhea were assessed for receipt of topical and/or oral antibiotics within 1 month of the otorrhea code per MarketScan REDBOOK generic identification numbers. Adherence was defined as topical antibiotics prescribed within 1 month of an otorrhea code. Nonadherence was defined as oral antibiotics prescribed within 1 month of the otorrhea code, with exceptions if the patient had the following conditions as listed in the guideline: cellulitis of the pinna or adjacent skin bacterial infection, severe infection, compromised immunity. There are no codes for otorrhea that worsens despite topical antibiotics, cost considerations, or inability to administer topical antibiotics. For all statements, data on sex, age, and seasonal and regional variations were extracted. Perioperative education regarding tube care and water precautions (KASs 10 and 12, respectively) could not be assessed through the database.
Each statement was analyzed in a descriptive fashion by tabulating frequencies and rates of compliance according to age, month of first visit, geographic region, and plan type. Where indicated, the Pearson chi-square test was used to compare frequencies of compliance between specified groups.
All analyses were performed with SAS 9.4 (Cary, North Carolina). All statistical tests were 2-sided, and a P value .05 was considered statistically significant.
Results

Analysis of Statements Pertaining to Tympanostomy Tube Placement
A total of 9,726,411 visits with codes associated with OM in 3,710,730 patients aged 0 to 12 years were identified. After exclusions of tympanic membrane perforations and otorrhea at first visit, a total of 3,239,700 episodes of OME in 2,692,742 patients remained; 2.9% of patients (80,451) had PET placement for an episode of OME \3 months and were classified as nonadherent to KAS 1 ( Table 1) . When viewed by episode (patients could have .1 episode), 2.5% (82,576) of episodes were not in adherence with KAS 1. Nonadherent episodes occurred in more males than females (59% vs 41%). Patients aged 2 years had a disproportionately higher number of episodes and nonadherence management (P \ .0001; Figure 2 , Table 2 ). Significant increases in nonadherence were noted in winter and the southern region (P \ .0001; Figure 3 , Table 2 ).
Of patients who had OME for .3 months with hearing loss, 52.1% (14,534 of 27,913) were adherent to KAS 3. Among those without hearing loss who underwent PET placement, 24.1% (109,583) had a symptom that was attributable to OME (KAS 4); 12.4% were at risk for speech, language, or learning problems (KAS 9). 
Geographic Region Division States included Mean (SD) Median (Q1, Q3) Minimum (%) Maximum (%)
Northeast New England CT, MA, ME, NH, RI, VT 2.0% (0. Among analyzed patients, 4.5% (107,038 of 2,372,828) were at risk for speech, language, or learning problems (KAS 8).
When the PET placement criteria were explored sequentially, the overall nonadherence rate dropped from 2.9% to 1.5%. Additionally, when exclusions were applied for patients who were classified as ''OME for 3 months with no hearing loss,'' nonadherence dropped from 23.1% to 12% (Figure 4) . KASs 6 and 7 address management for patients with recurrent AOM without and with MEE. Among patients with recurrent AOM (106,221), 22.4% had no hearing loss code (our surrogate for MEE) at last visit and yet underwent PET placement, which is not adherent to KAS 6. Of patients with AOM and MEE at last visit, 44.2% underwent PET placement within 6 months of last visit, which is considered adherent with KAS 7.
Analysis of Statements Pertaining to Medical Management
The CPG recommends that patients with chronic OME have an audiogram and, if a PET is not placed, be followed. In sum, 13.5% (81,442 of 603,785) of episodes of OME .3 months were associated with a hearing test between 3 and 6 months of first visit (KAS 2); 14.5% of episodes of chronic OM (episode lasting .3 months) did not undergo PET placement, and 6.0% of these patients had at least 1 code for hearing loss or structural abnormalities. Of this group, 91.6% remained under surveillance for complications of OME, as recommended in KAS 5.
For patients who received PET and had a subsequent code for otorrhea, 18.7% (16,242 of 86,947) were prescribed topical or oral antibiotics within 1 month of an otorrhea code. Most of these patients (95.4%) were given topical antibiotics and complied with KAS 11. A total of 754 patients were prescribed oral antibiotics; 34.9% of these also had a code for concurrent infection or history of being immunocompromised.
Discussion
Our analysis of a large health care claims database (MarketScan) shows high compliance and low nonadherence to the AAO-HNSF CPG for PET insertion in OME. 2 We used a retrospective-prospective analysis approach and tracked patients from the index diagnosis to the index event for each guideline statement. We considered the direction of the guideline statement; each provided recommendations regarding what action should or should not be considered adherent to its described purpose.
Our analysis differs significantly from previous studies and is relevant for comparing the interpretation of physician adherence with PET indications. 6, 7 The availability of comprehensive national claims metadata enables new analytic strategies to evaluate US health care practices broadly. Our rationale for using this approach is that aggregated metadata from the electronic health record are used to inform policy and initiatives. These new ''big data'' analytic capabilities and strategies (1) are timely yet retrospective, (2) link to episodes of care and associated cost, and (3) could be powerful tools to assess changes in practice resulting from new validated research and/or policy.
Previous studies evaluated tympanostomy tube insertion based on criteria derived from expert consensus guidelines on management of OM. The analytic strategy in these studies begins with the index event and looks retrospectively for clinical and diagnostic evidence to support appropriateness assessment. In the Kleinman et al study, a sampling strategy of all cases of proposed tympanostomy tube insertion was used to evaluate appropriateness. 7 Keyhani et al selected a population of patients who received PET, and they performed retrospective analysis of data for 1 year to determine appropriateness of the procedure. Both author teams concluded that the majority of tympanostomy tube insertions were inappropriate, basing their conclusion on a scoring algorithm stratified by hearing status and antibiotic treatment.
In both studies, the OM disease management guideline evaluated PET insertion appropriateness. Our study used a PET intervention guideline to evaluate disease management (nonadherence assessment).
Furthermore, the population considered in their analyses was fundamentally different from ours. Our denominator was patients coded with OM, while they used the patients who underwent PET insertion. Our approach frames nonadherence of PET indications within the context of all OME patients. Our analysis strategy could be considered the negative of previous authors; we evaluated when not to place a PET (KAS 1) and when hearing loss is not present (KAS 3). Most subsequent KASs qualify the above to arrive at the estimate of episodes of care that did not meet criteria based on our available information.
Our results show low estimates of nonadherence of PET placement within the studied population of pediatric patients with OME. Of note is that our overall population estimate of patients who received PET is similar and supports the published estimates of PET insertion (5.1% vs 6%).
We also examined sex, age, and seasonal and regional variations to determine whether these factors affected the rate of OM or influenced PET placement. Our finding of increased episodes of OM in children aged 2 years is consistent with other studies, 3 as is our finding that nonadherence was higher in the south. 1 Analysis of the 12 KASs in a stepwise fashion revealed the impact of the qualifying KASs that should be considered in the assessment of nonadherence. A stepwise analysis of coded diagnoses adjusted the nonadherence rate downward significantly. These qualifying KASs included known risk factors and associations with OM, such as developmental delay, delayed speech and language development, 5 and other symptoms, including vestibular problems and chronic ear pain (Figure 4) .
Two KASs that related specifically to medical management/evaluation showed potential opportunities for quality improvement. Only 13.5% of OME episodes .3 months had an associated hearing test (KAS 2). Most patients with otorrhea had a prescription for topical antibiotics (95.4%). However, about two-thirds of patients who received oral antibiotics did not have a coded comorbid condition or diagnosis other than OM.
There are several unique and important features in this study, including the use of a large national database with information from millions of patient encounters. We analyzed episodes of care and individual patients, which enabled the retrospective prospective study design, and we examined nonadherence based on disease management of a population of patients rather than a subpopulation who received PET. Results from the latter strategy can be biased toward lack of compliance and are not as generalizable to the greater population of patients with OM.
Although the overall percentage of nonadherence in our study is small (5.1% combined nonadherence for 137,113 of 2,692,742 patients), the burden of disease is great and translates to 137,113 procedures over the period of the study. With the estimated cost of PET placement at $2700, the total direct cost is .$370 million.
Limitations of this study include the presence of physician coding variability and the inability to directly determine important physical examination findings, such as the presence of a MEE. Additionally, we had to define an episode of care to frame the analysis of nonadherence. We used the definitions set forth in the guideline; some required subjective assessment and relational logic to determine the most proximal surrogate code for the specified finding or action. This is most apparent in KASs 10 and 12, which give guidance on education and expectations as well as water precautions. We could not evaluate these statements, since our database does not contain these variables, nurse notes, or patient education tasks.
We hope that studies like ours can help the developers of evidence-based guidelines and electronic health record vendors improve patient care and documentation by providing an integrated disease-specific ''code set.'' This code set should approximate the true state of care more accurately, improve quality through coding, and potentially facilitate integration and translation of research and evidence into best clinical practice. Despite its limitations, analysis of this megadatabase allowed for determination of nonadherence metrics and assessment of how the KAS of the CPG interact.
Conclusion
A mega-database can be used to explore practice patterns and measure guideline nonadherence. Analysis of the MarketScan databases revealed low rates of nonadherence in regard to PET placement. Our stepwise KAS analysis strategy allowed qualifying KAS in assessment of the overall nonadherence rate. There were performance gaps identified in our study pertaining to audiologic evaluation of patients with OM .3 months as well as antibiotic therapy in treatment of otorrhea. Despite the low nonadherence rate for placement of tympanostomy tubes, there remain opportunities for quality improvement and better resource management. Similar analyses of data collected after the publication of the 2013 AAO-HNSF CPG are needed to determine the impact of the guideline on clinical practice. We believe that nonadherence evaluation within the population of interest is a valid, generalizable, and important analysis strategy for evaluating disease management at a policy and health services research level.
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